Prakash Gupta

Dr. Prakash Gupta is an associate research scientist in the Schizophrenia Neuropharmacology Research Group at Yale (SNRGY lab). He trained in medicine at the All India Institute of Medical Sciences, New Delhi.

Dr. Gupta’s research explores the therapeutic potential of psychedelics in mental illness through clinical trials. He currently leads the effort for a phase 1 clinical trial investigating the safety, tolerability, electrophysiological effects and efficacy of intravenous DMT in humans. In parallel, he coordinates studies examining how genetic factors and aging influence the response to cannabis and contribute to changes in cognition, sleep, and vulnerability to addiction and psychosis. In parallel, he coordinates studies examining how genetic factors and aging shape responses to cannabis, including effects on cognition and sleep and vulnerability to addiction and psychosis. His work also utilizes PET neuroimaging to understand if hippocampal synaptic density recovers with sustained abstinence in individuals with cannabis use disorder.